After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase inhibitors are beginning.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Synthesis, docking, MD simulation, ADMET, drug likeness, and DFT studies of novel furo[2,3-b]indol-3a-ol as promising Cyclin-dependent kinase 2 inhibitors
Scientific Reports Open Access 07 February 2024
-
A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
Laboratory Investigation Open Access 17 December 2021
-
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
Cell Death & Differentiation Open Access 17 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Guha, M. Cyclin-dependent kinase inhibitors move into Phase III. Nat Rev Drug Discov 11, 892–894 (2012). https://doi.org/10.1038/nrd3908
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3908
This article is cited by
-
Synthesis, docking, MD simulation, ADMET, drug likeness, and DFT studies of novel furo[2,3-b]indol-3a-ol as promising Cyclin-dependent kinase 2 inhibitors
Scientific Reports (2024)
-
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
Cell Death & Differentiation (2022)
-
A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
Laboratory Investigation (2022)
-
Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma
Scientific Reports (2018)
-
The use of novel selectivity metrics in kinase research
BMC Bioinformatics (2017)
